EUVIMEDEUVIMED entdecken
Crossref

Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer Activity

Hazem Elkady iD, Walid E Elgammal iD, Ibrahim H Eissa iD, Hazem A Mahdy iD, Aisha A Alsfouk iD, Fatma G Amin iD, Dalal Z Husein iD, Ahmed M Metwaly iD, Eslam B Elkaeed iD

Drug Development Research · 2026-05 · 87 (3)

DOI: 10.1002/ddr.70297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, online erschienen am 03.05.2026. Verfasst von Hazem Elkady und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt. Hauptthemen laut MEDLINE: Vascular Endothelial Growth Factor Receptor-2, Benzopyrans, Antineoplastic Agents, Angiogenesis Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Princess Nourah bint Abdulrahman University Researchers, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In this study, a novel series of chromene‐based derivatives was rationally designed as potential VEGFR‐2 inhibitors based on key structural and pharmacophoric features required for antiangiogenic activity. Accordingly, twelve chromene derivatives ( 13a–e, 15a–e , and 17a–b ) were successfully synthesized and structurally characterized. The synthesized compounds were evaluated in vitro for their cytotoxic activity against human cancer cell lines (MCF‐7, HepG‐2, and HCT‐116), in addition to normal WI‐38 and WISH cells. Among the tested compounds, compound 13a demonstrated the most potent and selective antiproliferative activity, exhibiting low micromolar IC 50 values and favorable selectivity indices. Enzymatic assays confirmed its VEGFR‐2 inhibitory activity (IC 50 = 1.666 ± 0.025 µM), comparable to the reference drug sorafenib. Mechanistic investigations revealed that compound 13a effectively inhibited cancer cell migration in a wound healing assay, highlighting its potential antiangiogenic properties. Furthermore, compound 13a induced significant G0/G1 cell cycle arrest in MCF‐7 cells and triggered apoptosis, as evidenced by Annexin V/PI staining. To support the experimental findings, Density Functional Theory (DFT) calculations confirmed favorable structural stability and electronic properties. Molecular docking studies demonstrated strong binding interactions within the VEGFR‐2 ATP‐binding site. These results were further validated by 200 ns molecular dynamics simulations, MM‐GBSA binding free energy calculations, Protein–Ligand Interaction Fingerprints (Pro‐LIF), Principal Component Analysis of Trajectories (PCA‐T), and Free Energy Landscape (FEL) analyses, confirming the dynamic stability and favorable energetics of the VEGFR‐2– 13a complex. Overall, this integrated experimental and computational study identifies compound 13a as a promising VEGFR‐2–targeted anticancer lead warranting further preclinical investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vascular Endothelial Growth Factor Receptor-2BenzopyransAntineoplastic AgentsAngiogenesis InhibitorsProtein Kinase InhibitorsHumansStructure-Activity RelationshipDrug DesignCell ProliferationMolecular Docking SimulationApoptosisCell Line, TumorCell MovementMCF-7 Cells

Stichwörter der Autor:innen

VEGFR‐2angiogenesisapoptosischromenein silicoin vitro

Substanzen

Vascular Endothelial Growth Factor Receptor-2BenzopyransAntineoplastic AgentsKDR protein, humanAngiogenesis InhibitorsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Pharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.
  • Department of Chemistry, Faculty of Science, Al-Azhar University, Nasr City, Cairo, Egypt.
  • Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
  • Physics Department, Faculty of Science, Alexandria University, Alexandria, Egypt.
  • Chemistry Department, Faculty of Science, New Valley University, El-Kharja, Egypt.
  • Pharmacognosy and Medicinal Plants Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo, Egypt.

ORCID-Profile: Hazem Elkady, Walid E Elgammal, Ibrahim H Eissa, Hazem A Mahdy, Aisha A Alsfouk, Fatma G Amin, Dalal Z Husein, Ahmed M Metwaly, Eslam B Elkaeed

Förderung

  • Princess Nourah bint Abdulrahman University Researchers
  • Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

Zitieren

APA

Elkady, H., Elgammal, W. E., Eissa, I. H., Mahdy, H. A., Alsfouk, A. A., Amin, F. G., Husein, D. Z., Metwaly, A. M., & Elkaeed, E. B. (2026). Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer Activity. Drug Development Research, 87(3). https://doi.org/10.1002/ddr.70297

Vancouver

Elkady H, Elgammal WE, Eissa IH, Mahdy HA, Alsfouk AA, Amin FG, et al. Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer Activity. Drug Development Research. 2026;87(3). doi:10.1002/ddr.70297

BibTeX
@article{Elkady2026,
  author = {Elkady, Hazem and Elgammal, Walid E and Eissa, Ibrahim H and Mahdy, Hazem A and Alsfouk, Aisha A and Amin, Fatma G and Husein, Dalal Z and Metwaly, Ahmed M and Elkaeed, Eslam B},
  title = {Structure‐Guided Design and Mechanistic Elucidation of New Chromene Derivatives as Selective Vascular Endothelial Growth Factor Receptor‐2 Inhibitors With Potent Anticancer Activity},
  journal = {Drug Development Research},
  year = {2026},
  volume = {87},
  number = {3},
  doi = {10.1002/ddr.70297}
}
Kostenlos starten →